We kick off the week with some news from Switzerland and introduce the new longevity biotech company builder Maximon.
The enthusiasm for technologies to promote longevity and even increase healthy human lifespan seems to be rising in Switzerland. There are frequently articles in the popular press about the topic and we were even asked to write an article for Schweizer Monat (Swiss Month) in February 2020 called “The ways to longevity“, which took a look at the near-future longevity tech that could change how we age.
We include the official press release below and let it do most of the talking, but in a nutshell, Maximon is a Switzerland-based biotech incubator that aims to identify and develop promising biotech companies that focus on creating therapies that target the aging processes and thus increase healthy longevity through the delaying, prevention, or even reversal of age-related diseases.
There are now a number of longevity company builders around the world, all of which approach things in a slightly different way. The arrival of Maximon is most welcome and they appear to be taking a more hands-on approach to building the actual companies from the ground up.
The more companies focused on developing technologies and therapies to support healthy longevity, the better; quite simply, the more rejuvenation startups there are, the greater the chances that one of them will succeed in the near future and show the world that human aging is not a one-way street and that we may have a choice regarding how we age in the next few decades.
Maximon launches the world’s first longevity company builder
Zug/Switzerland, March 8th, 2021 – Maximon is the new company builder based in Switzerland with the aim to extend the health-span and to allow humans to reach a fit, healthy and happy longevity.
Maximon will start several companies per year and provide a comprehensive set of resources that empowers founders to focus on and create superior services and products and execute at speed on a global scale. The resulting company cluster is highly synergetic and allows Maximon to impact the longevity sector from multiple angles simultaneously. Maximon plans to allocate CHF 50million+ over the next 4 years and to raise a larger longevity focused fund thereafter.
“Longevity will be one of the largest, if not the largest, investment opportunities in the decades to come. At Maximon, we want to monetize this huge business opportunity by empowering entrepreneurs to build impactful, science-based and scalable companies that investigate and perpetuate healthy aging and rejuvenation solutions”, says Founding Partner Dr. Tobias Reichmuth. “The recent progress in science relating to life and health extension is very impressive and creates unique and massive business opportunities”, adds the Founding Partner Marc P. Bernegger.
The founding team is complemented by serial entrepreneur and investor Jörg Rieker, venture building expert Caroline Faisst, and three additional team-members.
Maximon is supported by a scientific advisory board consisting of Prof. Dr. Collin Ewald from ETH Zurich and Prof. Dr. Evelyne Yeudit Bischof, MD, MPH from Shanghai University of Medicine and Health Sciences and Human Longevity Inc., by industry advisors like Adrian Locher (Co-Founder of DeinDeal and Merantix) and Alexander Thiel (Partner and Lead Consumer Goods Practice at McKinsey & Company).
Dr. Tobias Reichmuth and Marc P. Bernegger are also the initiators of the “Longevity Investors Conference”, which targets the global investor community.
Maximon is a longevity company builder based in Switzerland with the mission to become the leading player in the field of longevity and healthy lifespan by empowering entrepreneurs to build impactful, science-based and scalable companies, which provide healthy aging and rejuvenation solutions.More information about Maximon can be found on www.maximon.com
Longevity is the science of anti-aging research and rejuvenation and has experienced an unprecedented advance over recent years, particularly with the discovery that the rate of aging is controlled, at least to some extent, by genetic pathways and biochemical processes. Longevity identifies both lifestyle and pharmaceutical targets to improve the human health-span (i.e. the time we can live without any negative impact from aging).
Email: [email protected]